These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23499430)

  • 1. Combined temozolomide and sunitinib treatment leads to better tumour control but increased vascular resistance in O6-methylguanine methyltransferase-methylated gliomas.
    Czabanka M; Bruenner J; Parmaksiz G; Broggini T; Topalovic M; Bayerl SH; Auf G; Kremenetskaia I; Nieminen M; Jabouille A; Mueller S; Harms U; Harms C; Koch A; Heppner FL; Vajkoczy P
    Eur J Cancer; 2013 Jun; 49(9):2243-52. PubMed ID: 23499430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
    Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
    Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
    Roos WP; Batista LF; Naumann SC; Wick W; Weller M; Menck CF; Kaina B
    Oncogene; 2007 Jan; 26(2):186-97. PubMed ID: 16819506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
    Pan Q; Yang XJ; Wang HM; Dong XT; Wang W; Li Y; Li JM
    Cell Biochem Biophys; 2012 Jan; 62(1):185-91. PubMed ID: 21892781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation.
    Natsume A; Wakabayashi T; Ishii D; Maruta H; Fujii M; Shimato S; Ito M; Yoshida J
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):653-9. PubMed ID: 17564708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
    Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
    BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifaceted resistance of gliomas to temozolomide.
    Bocangel DB; Finkelstein S; Schold SC; Bhakat KK; Mitra S; Kokkinakis DM
    Clin Cancer Res; 2002 Aug; 8(8):2725-34. PubMed ID: 12171906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
    Remington M; Chtchetinin J; Ancheta K; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2009 Feb; 11(1):22-32. PubMed ID: 18812520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase.
    Fukai J; Koizumi F; Nakao N
    PLoS One; 2014; 9(8):e104538. PubMed ID: 25111384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas.
    Fan CH; Liu WL; Cao H; Wen C; Chen L; Jiang G
    Cell Death Dis; 2013 Oct; 4(10):e876. PubMed ID: 24157870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EphB4 mediates resistance to antiangiogenic therapy in experimental glioma.
    Uhl C; Markel M; Broggini T; Nieminen M; Kremenetskaia I; Vajkoczy P; Czabanka M
    Angiogenesis; 2018 Nov; 21(4):873-881. PubMed ID: 29987450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
    Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
    Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
    Minea RO; Duc TC; Swenson SD; Cho HY; Huang M; Hartman H; Hofman FM; Schönthal AH; Chen TC
    PLoS One; 2020; 15(9):e0238238. PubMed ID: 32881880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
    Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
    J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
    Hermisson M; Klumpp A; Wick W; Wischhusen J; Nagel G; Roos W; Kaina B; Weller M
    J Neurochem; 2006 Feb; 96(3):766-76. PubMed ID: 16405512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas.
    Yoshino A; Tashiro S; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Sano E; Tsumoto K
    Int J Oncol; 2011 Sep; 39(3):529-42. PubMed ID: 21805051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
    Hirose Y; Kreklau EL; Erickson LC; Berger MS; Pieper RO
    J Neurosurg; 2003 Mar; 98(3):591-8. PubMed ID: 12650433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.
    Zhou Q; Gallo JM
    Neuro Oncol; 2009 Jun; 11(3):301-10. PubMed ID: 18971416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
    Gander M; Leyvraz S; Decosterd L; Bonfanti M; Marzolini C; Shen F; Liénard D; Perey L; Colella G; Biollaz J; Lejeune F; Yarosh D; Belanich M; D'Incalci M
    Ann Oncol; 1999 Jul; 10(7):831-8. PubMed ID: 10470431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.